한글목차

세계의 바이러스 벡터 제조 시장 규모는 2025년 63억 달러에서 2025-2030년의 예측 기간 중 CAGR 24.6%로 추이하며, 2030년말에는 188억 달러에 달할 것으로 예측됩니다.

북미 시장은 2025년 34억 달러에서 예측 기간 중 CAGR 25.7%로 추이하며, 2030년말에는 107억 달러에 달할 것으로 예측됩니다. 유럽 시장은 2025년 15억 달러에서 예측 기간 중 21.5%의 CAGR로 추이하며, 2030년말에는 40억 달러에 달할 것으로 예측됩니다.

세계의 바이러스 벡터 제조 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석 등을 정리하여 전해드립니다.

목차

제1장 개요

• 시장 전망
• 조사 범위
• 시장 요약
• 시장 역학과 성장요인
• 신규 기술
• 부문 분석
• 지역 분석
• 결론

제2장 시장 개요

• 개요
• 거시경제 요인
• 미국 관세의 제약 업계에 대한 영향
• 의료비
• 세계 경제 성장(GDP)의 제약 업계에 대한 영향
• 직접적 영향
• 간접적 영향
• Porter's Five Forces 분석

제3장 시장 역학

• 시장 역학
• 시장 성장 촉진요인
• 만성질환의 발생률 증가
• 벡터 기반 치료의 승인
• 바이러스 벡터 제조의 수요
• 시장 성장 억제요인
• 바이러스 벡터 개발에서 프로세스와 비용 장벽
• 바이러스 벡터에 관한 기술적 보틀넥
• 바이러스 벡터 제조에 수반하는 고비용
• 시장 기회
• 새로운 바이러스 기반 치료
• 바이러스 벡터 제조 디지털화

제4장 규제 상황

• 개요
• 미국
• 유럽
• 일본

제5장 신규 기술과 파이프라인 분석

• 개요
• 자동화
• 차세대 제조 시스템
• 유전자 편집
• 파이프라인 분석
• 특허 분석

제6장 시장 세분화 분석

• 세분화 내역
• 세계의 바이러스 벡터 제조 시장 : 유형별
• 렌티바이러스 벡터
• 아데노바이러스 벡터
• 아데노연관바이러스 벡터
• 레트로바이러스 벡터(RV)
• 기타 바이러스 벡터
• 세계의 바이러스 벡터 제조 시장 : 용도별
• 다가 바이러스 벡터 백신
• 다병원체 바이러스 벡터 백신
• 세계의 바이러스 벡터 제조 시장 : 질환별
• 동물 질병
• 인간 질병
• 지역적 내역
• 세계의 바이러스 벡터 제조 시장 : 지역별
• 북미
• 유럽
• 아시아태평양
• 중동 및 아프리카
• 남미

제7장 경쟁 정보

• 시장 점유율 분석

제8장 바이러스 벡터 제조업계에서의 지속가능성 : ESG의 관점

• ESG : 서론
• 바이러스 벡터 제조에서의 지속가능성
• ESG의 시점
• 환경에 대한 영향
• 폐기물 관리
• 사회에 대한 영향
• 거버넌스의 영향
• ESG 리스크 평가
• 결론

제9장 부록

• 조사 방법
• 약어
• 전시
• 기업 개요
• ABL INC.
• CATALENT INC.
• CHARLES RIVER LABORATORIES
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• LONZA
• MERCK KGAA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC.
• PROBIO
• REVVITY
• SANOFI
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.
• 바이러스 벡터 제조 신규 기업

영문목차

The global market for viral vector manufacturing is expected to grow from $6.3 billion in 2025 and is projected to reach $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 24.6% during the forecast period of 2025 to 2030.

The North American market for viral vector manufacturing is expected to grow from $3.4 billion in 2025 and is projected to reach $10.7 billion by the end of 2030, at a CAGR of 25.7% during the forecast period of 2025 to 2030.

The European market for viral vector manufacturing is expected to grow from $1.5 billion in 2025 and is projected to reach $4 billion by the end of 2030, at a CAGR of 21.5% during the forecast period of 2025 to 2030.

Report Scope

This report analyzes viral vector manufacturing market trends using 2024 data, 2025 estimates, market projections and compound annual growth rates (CAGRs) for the forecast period of 2025-2030. The report discusses viral vector manufacturing's current and future market potential and covers regulatory scenarios, drivers, restraints, and opportunities.

The report segments the market by type, application and disease. Types include adenoviral vectors (AdVs), adeno-associated viral vectors (AAVs), lentiviral vectors (LVs), retroviral vectors (RVs), and other viral vectors. Applications consist of multivalent and multipathogen. Diseases are segmented into human and veterinary. Human diseases are further segmented into HIV, tuberculosis, cancer, influenza, malaria, hepatitis, and others. Veterinary diseases are further segmented into avian influenza, Marek's disease, infectious bronchitis, and PPR disease.

The market has been segmented into the regions of North America, Europe, Asia-Pacific, the Middle East and Africa (MEA), and South America. The markets of individual countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India, are analyzed.

The goals of the report are to:

• Analyze types of viral vectors.
• Calculate the size of the global market size, with forecasts through 2030.
• Identify market constraints and drivers.
• Assess company's market shares, competitiveness, and industry structure.
• Identify potential long-term impacts on the viral vector manufacturing market.

Report Includes

• Overview and analysis of the global viral vector manufacturing markets and technologies
• Analyses of the global market trends, with historic sales revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Estimates of the market's size and revenue prospects, accompanied by a market share analysis based on type, application, disease segment and region
• Facts and figures pertaining to market dynamics, technological advancements, regulations, prospects, and the impacts of macroeconomic variables
• Insights derived from Porter's Five Forces model and global value chain analysis
• An assessment of the viral vaccine pipeline products, clinical trials, competitive scenario and R&D activities
• An analysis of patents, emerging trends and new developments in the industry
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
• Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, and M&A activity
• Profiles of the leading companies

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factors
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditures
• Impact of Global Economic Growth (GDP) on Pharma Sector
• Direct Economic Impact
• Indirect Economic Impact
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants to Market
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Incidence of Chronic Diseases
• Approvals of Vector-Based Therapies
• Demand for Viral Vector Production
• Market Restraints
• Process and Cost Barriers in Viral Vector Development
• Viral Vector Roadblocks
• High Cost Linked with Viral Vector Production
• Market Opportunities
• Emerging Viral-Based Therapies
• Digitalization in Viral Vector Production

Chapter 4 Regulatory Landscape

• Overview
• United States
• Europe
• Japan

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Automation
• Next-Generation Production Systems
• Genome Editing
• Pipeline Analysis
• Takeaways
• Patent Analysis
• Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Viral Vector Manufacturing by Type
• Lentiviral Vectors
• Adenoviral Vectors
• Adeno-Associated Viral Vectors
• Retroviral Vectors (RVs)
• Other Viral Vectors
• Global Viral Vector Manufacturing Market, by Application
• Multivalent Viral Vector Vaccines
• Multipathogen Viral Vector Vaccines
• Global Market for Viral Vector Manufacturing, by Disease
• Veterinary Diseases
• Human Diseases
• Geographic Breakdown
• Global Market for Viral Vector Manufacturing, by Region
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Market Share Analysis
• Market Share Analysis
• Recent Developments

Chapter 8 Sustainability in the Viral Vector Manufacturing Industry: An ESG Perspective

• Introduction to ESG
• Sustainability in the Viral Vector Manufacturing Industry
• ESG Perspective
• Environmental Impact
• Waste Management
• Social Impact
• Governance Impact
• ESG Risk Ratings
• Conclusion

Chapter 9 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABL INC.
• CATALENT INC.
• CHARLES RIVER LABORATORIES
• DANAHER CORP.
• F. HOFFMANN-LA ROCHE LTD.
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• LONZA
• MERCK KGAA
• NOVARTIS AG
• OXFORD BIOMEDICA PLC.
• PROBIO
• REVVITY
• SANOFI
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.
• Emerging Players in the Viral Vector Manufacturing Market